ValiRx secures cash to fund VAL201 trial through to completion
In total, European High Growth Opportunities Securitisation Fund has agreed to make at least £7.3mln available to ValiRx bosses
Company
ValiRx PLC
LON:VAL
ValiRx is a drug development company, which focuses on the translation of scientific innovation into clinical candidates for cancer, related conditions and women’s health. The company's specialised business model connects science, finance and commerce to accelerate early-stage drug development. It identifies proprietary and novel drug candidates with the potential to improve patient lives, providing the expertise and investment required for optimised development and value creation.
310 stories · page 4 of 16
Investments and investor services
Exillon Energy plunges after it calls in advisors to go over its accounts with a fine-toothed comb
A look at the day's major movers, including Bidstack, EU Supply, ReNeuron, Inspirit Energy, Prospex, Ferrexpo and Hastings Group
Archive
Proactive news snapshot: ReNeuron, Union Jack Oil, ANGLE, ECR Minerals …
A glance at some of the day's highlights from the Proactive Investors newswire
ValiRx primed for a pivotal year
Proactive takes a closer look at an innovative drugs company that has largely flown under the radar
Investments and investor services
Carnival sinks as it lowers full-year guidance
A look at the day's major movers, including Quartix, LiDCO, Convatec, PPHE, Boku and Coral Products
Archive
Proactive news snapshot: ValiRx, Erris Resources, Personal Group, S&U …
A glance at some of the day's highlights from the Proactive Investors newswire
Valirx says letters of intent signed to fund final stage trial of lung cancer drug
One European and one US group have the signed letters of intent for funding
Investments and investor services
WH Ireland claws back some recent losses as shareholders OK fund-raising
A look at the day's major movers, including Cadence Minerals, FW Thorpe, IG Group, LPA, Integrated Diagnostics, Wynnstay and Clear Leisure
Archive
Proactive news snapshot: ValiRx, LoopUp Group, Kibo Energy …
A glance at some of the day's highlights from the Proactive Investors newswire
ValiRx boss “delighted” with progress of cancer drug VAL201 and VAL301 for endometriosis
VAL201 is coming towards the end of a Phase I/II study, while VAL301 is in late pre-clinical development
ValiRx raises £0.5mln in share placing to further expand scope of clinical trial for its prostate cancer treatment
The AIM-listed clinical stage biotechnology said its company broker, Novum Securities issued 83,333,333 new ordinary shares at a price of 0.6p each with new and existing investors
Archive
Proactive news snapshot: Faron Pharmaceuticals, Sunrise Resources, Tertiary Minerals …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: BigDish, ValiRx, Oriole Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Sylvania Platinum fails to flatten 'em - the sceptics, that is - with its production update
A look at the day's major movers, including Cambridge Cognition, SRT Marine, Redhall, FireAngel, Challenger Acquisitions, Alexander Mining and Blue Star Capital
ValiRx surges as it secures two new patents for VAL301 in Russia and China
The patents protect VAL301 as a treatment for endometriosis and prostate enlargement in two of the world’s most populous countries
Archive
Proactive news snapshot: Stobart Group, Berkeley Energia, ANGLE …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Lighthouse Group succumbs to profit taking
A look at the day's major movers, including Bidstack, NAHL, Flybe, Stobart Group and AO World
ValiRX confirms online publication of peer-reviewed article
VAL401 is a new formulation of the antipsychotic drug risperidone
Investments and investor services
FTSE 100 closes in red but nudges higher on the week; housebuilders gain on day
The UK blue-chip benchmark closed down around 24 points at 6,918, while FTSE 250 added nearly 107 points on the day
New long-term NHS plan bodes well for ValiRx
The ten-year plan, set out on Monday, includes a greater focus on earlier detection of cancers and personalised medicines, both of which ValiRx specialises in